Top 20 biopharma uses Veeva Development Cloud to accelerate the development of therapies for currently incurable diseases
Boehringer Ingelheim and Veeva Systems announced the launch of Boehringer’s One Medicine Platform, built on the successful implementation of the Veeva Development Cloud . They first announced the One Medicine collaboration in March 2022. The unified platform brings together clinical, regulatory, and quality data and processes, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research institutions, and accelerate the delivery of new medicines to treat currently incurable diseases.
“Together with Veeva, Boehringer has evolved its approach to clinical trials, fulfilling our promise to accelerate the delivery of innovative, life-changing treatments to patients around the world,” said Oliver Fink , Head of Learning, Operations, and Digitalization at Boehringer Ingelheim. “Veeva Development Cloud forms the technological foundation for Boehringer’s One Medicine Platform, giving our teams the flexibility to develop and execute trials faster, more efficiently, and more compliantly.”
Also Read: 2seventy bio to Be Acquired by Bristol Myers Squibb
“By connecting clinical, regulatory, and quality aspects in the Veeva Development Cloud, Boehringer is unifying data and breaking down silos between teams to accelerate drug development and approval,” said Rik van Mol, senior vice president, Veeva Development Cloud. “This is an exciting milestone in realizing Veeva and Boehringer’s shared goal of advancing the use of data and technology to modernize clinical trials and deliver better outcomes for patients.”
Veeva Development Cloud is the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and enable process optimization.
Source: PRNewswire